A kernelisation approach for multiple d-Hitting Set and its application in optimal multi-drug therapeutic

Drew Mellor1, Elena Prieto, Luke Mathieson

  • 1Centre for Bioinformatics, Biomarker Discovery and Information Based Medicine, The University of Newcastle, Newcastle, Australia.

Plos One
|October 27, 2010
PubMed

Insights

Computational methods can identify effective cancer drug combinations faster and more affordably. We introduce a new Hitting Set problem formulation that is computationally tractable for practical applications in drug discovery.

Area of Science:

  • Computational biology
  • Combinatorial optimization
  • Cancer therapy

Background:

  • Developing effective combination therapies for complex diseases like cancer is crucial but costly.
  • Traditional methods for identifying drug combinations are time-consuming and expensive.
  • Computational approaches can accelerate the discovery of promising drug combinations.

Purpose of the Study:

  • To introduce a generalized Hitting Set problem, termed (α,β,d)-Hitting Set, for efficient drug combination selection.
  • To analyze the computational complexity of the (α,β,d)-Hitting Set problem using Parameterized Complexity.
  • To demonstrate the practical applicability and scalability of this new method in cancer therapy.

Main Methods:

  • Formulated the (α,β,d)-Hitting Set problem, a generalization of the standard Hitting Set problem.
  • Applied Parameterized Complexity theory to prove fixed-parameter tractability for the (α,β,d)-Hitting Set problem.
  • Developed a kernelization for the problem with a kernel size of O(αdk(d)).

Main Results:

  • The (α,β,d)-Hitting Set problem is NP-complete but fixed-parameter tractable.
  • A kernelization exists, indicating scalability to large datasets.
  • Practical application in cancer drug selection yielded computation times of approximately 5 seconds, significantly faster than previous methods.

Conclusions:

  • The (α,β,d)-Hitting Set problem offers a computationally efficient and scalable approach for identifying optimal drug combinations.
  • This method accelerates drug discovery for complex diseases like cancer, reducing financial and temporal costs.
  • The fixed-parameter tractability and kernelization demonstrate the practical utility and scalability of the proposed computational framework.

Related Concept Videos

Pharmacokinetic–Pharmacodynamic Relationship: Problems01:24

Pharmacokinetic–Pharmacodynamic Relationship: Problems

The empirical approach to drug therapy optimization relies on correlating pharmacological response with administered dosage. Such an approach can be costly, time-consuming, and often yields poor correlation due to variables like formulation factors and drug elimination characteristics. A more precise approach correlates response with plasma drug concentration or the amount of drug in the body, rather than dosage. This is achieved through pharmacokinetic-pharmacodynamic (PK/PD) modeling, which...
Drug Discovery: Overview01:26

Drug Discovery: Overview

Drug discovery is a multifaceted process involving extensive screening, testing, and optimization of lead compounds to identify potential new drugs for therapeutic use. It combines several approaches, including screening large numbers of natural products, chemical modification of known active molecules, identification of new drug targets, and rational design based on biological mechanisms and drug-receptor structure. These approaches are carried out in both academic research laboratories and...
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
Combined Effects of Drugs: Synergism01:27

Combined Effects of Drugs: Synergism

Synergism is a useful mechanism where combining two or more drugs is more effective than each constituent used alone. Such combinations are also called supra-additive interactions. The drugs collectively enhance the final therapeutic effect by acting on different targets. Another advantage is that the low dose of each constituent drug is sufficient to achieve the desired effect. This helps reduce the duration of therapy and lower the adverse effects of these drugs.
Such synergistic combinations...
Bioequivalence of Drugs: Drugs with Multiple Indications01:09

Bioequivalence of Drugs: Drugs with Multiple Indications

The concept of therapeutic equivalence (TE) in drugs with multiple indications is complex. A generic drug may be therapeutically equivalent to a brand-name product for one specific indication, but this doesn't necessarily mean it's equivalent for all other indications. Evidence of TE in one patient group and bioequivalence shown in healthy volunteers can support—but not confirm—TE for other indications. However, definitive proof requires individual clinical studies for each indication due to...